ATXI · Avenue Therapeutics, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These factors individually and collectively cause substantial doubt about the Company's ability to continue as a going concern to exist within one year from the date of this report.”View the 10-Q filed Aug 7, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Apr 26, 2024; bars on opposite sides are not compared.
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ATXI
this stock
Avenue Therapeutics, Inc.
|
$848,783 | -62.1% | — | — | 0.2% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +19.3% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +13.7% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.4% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +17.5% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 5.8%
- Net QoQ
- -4.9K sh
- Top holder
- Ikarian Capital, LLC
Performance
Raw-price comparisons begin at the captured split on Apr 26, 2024; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ATXI | +3.0% | -21.9% | -61.6% | -33.6% | -62.1% |
| SPY | -0.1% | +4.1% | +12.4% | +3.4% | +13.3% |
| vs SPY | +3.1% | -26.1% | -74.0% | -37.0% | -75.4% |